Cegedim 将来の成長

Future 基準チェック /36

Cegedim利益と収益がそれぞれ年間49.8%と5.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に7.4% 50%なると予測されています。

主要情報

49.8%

収益成長率

50.0%

EPS成長率

Healthcare Services 収益成長	30.1%
収益成長率	5.2%
将来の株主資本利益率	7.4%
アナリストカバレッジ	Low
最終更新日	25 Oct 2024

今後の成長に関する最新情報

Recent updates

Does Cegedim's (EPA:CGM) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 06

Cegedim's (EPA:CGM) Stock Price Has Reduced 26% In The Past Three Years

Nov 23

業績と収益の成長予測

ENXTPA:CGM - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	722	27	34	117	3
12/31/2025	689	23	30	110	3
12/31/2024	653	18	36	102	3
6/30/2024	634	2	13	93	N/A
3/31/2024	625	-3	18	95	N/A
12/31/2023	616	-7	22	98	N/A
9/30/2023	602	1	26	104	N/A
6/30/2023	589	10	30	111	N/A
3/31/2023	572	12	20	99	N/A
12/31/2022	555	14	10	86	N/A
9/30/2022	548	14	-7	64	N/A
6/30/2022	541	15	-25	42	N/A
3/31/2022	533	21	3	69	N/A
12/31/2021	525	26	31	96	N/A
9/30/2021	518	24	36	106	N/A
6/30/2021	512	22	41	116	N/A
3/31/2021	504	16	39	113	N/A
12/31/2020	497	11	36	110	N/A
9/30/2020	496	10	28	98	N/A
6/30/2020	494	8	21	85	N/A
3/31/2020	499	5	-6	57	N/A
12/31/2019	504	3	-33	29	N/A
9/30/2019	495	-1	-8	54	N/A
6/30/2019	486	-5	18	80	N/A
3/31/2019	477	0	41	102	N/A
12/31/2018	468	4	65	124	N/A
9/30/2018	464	8	41	100	N/A
6/30/2018	461	12	18	77	N/A
3/31/2018	459	10	N/A	75	N/A
12/31/2017	457	7	N/A	73	N/A
9/30/2017	452	-13	N/A	82	N/A
6/30/2017	438	-17	N/A	78	N/A
3/31/2017	435	-12	N/A	76	N/A
12/31/2016	429	-29	N/A	59	N/A
9/30/2016	438	13	N/A	52	N/A
6/30/2016	435	9	N/A	55	N/A
3/31/2016	432	1	N/A	9	N/A
12/31/2015	426	19	N/A	40	N/A
9/30/2015	364	0	N/A	89	N/A
6/30/2015	380	-6	N/A	62	N/A
3/31/2015	399	-4	N/A	130	N/A
12/31/2014	412	-8	N/A	127	N/A
9/30/2014	161	-26	N/A	132	N/A
6/30/2014	266	-11	N/A	163	N/A
3/31/2014	377	-5	N/A	143	N/A
12/31/2013	488	-14	N/A	150	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CGMの予測収益成長率 (年間49.8% ) は貯蓄率 ( 1.4% ) を上回っています。

収益対市場: CGMの収益 ( 49.8% ) はFrench市場 ( 12.5% ) よりも速いペースで成長すると予測されています。

高成長収益: CGMの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: CGMの収益 ( 5.2% ) French市場 ( 5.6% ) よりも低い成長が予測されています。

高い収益成長: CGMの収益 ( 5.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CGMの自己資本利益率は、3年後には低くなると予測されています ( 7.4 %)。

Cegedim 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 15%

Price target decreased by 7.4% to €16.70

Cegedim SA Provides Earnings Guidance for the Full Year 2024

Price target decreased by 7.9% to €19.37

Consensus EPS estimates fall by 18%

Cegedim Provides Revenue Guidance for the Full Year 2023

Recent updates

Consensus EPS estimates increase by 15%

Cegedim SA to Report Fiscal Year 2024 Results on Mar 27, 2025

There May Be Reason For Hope In Cegedim's (EPA:CGM) Disappointing Earnings

First half 2024 earnings released: EPS: €0.046 (vs €0.64 loss in 1H 2023)

Price target decreased by 7.4% to €16.70

Cegedim SA Provides Earnings Guidance for the Full Year 2024

Cegedim SA's (EPA:CGM) CEO Will Probably Struggle To See A Pay Rise This Year

Price target decreased by 7.9% to €19.37

New major risk - Financial position

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings released: EPS: €0.051 (vs €0.68 in 3Q 2022)

Getting In Cheap On Cegedim SA (EPA:CGM) Might Be Difficult

Consensus EPS estimates fall by 18%

Cegedim SA to Report First Half, 2024 Results on Sep 26, 2024

First half 2023 earnings released: €0.64 loss per share (vs €0.36 loss in 1H 2022)

Cegedim Provides Revenue Guidance for the Full Year 2023

First half 2023 earnings released: €0.64 loss per share (vs €0.36 loss in 1H 2022)

New minor risk - Earnings quality

Cegedim SA Provides Revenue Guidance for the Full Year 2023

These 4 Measures Indicate That Cegedim (EPA:CGM) Is Using Debt Extensively

Consensus EPS estimates increase by 16%

When Should You Buy Cegedim SA (EPA:CGM)?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 7.1% to €21.40

Cegedim SA Provides Group Revenue Guidance for the Year 2023

Less than half of directors are independent

Cegedim SA to Report First Half, 2023 Results on Sep 20, 2023

Consensus forecasts updated

Cegedim SA to Report Fiscal Year 2022 Results on Mar 23, 2023

Consensus forecasts updated

Cegedim Provides Revenue Guidance for 2022

These 4 Measures Indicate That Cegedim (EPA:CGM) Is Using Debt Extensively

First half 2022 earnings released: €0.40 loss per share (vs €0.47 profit in 1H 2021)

Cegedim SA (ENXTPA:CGM) acquired Merito, SAS.

Upcoming dividend of €0.50 per share

Price target decreased to €28.83

Less than half of directors are independent

Cegedim, Malakoff Humanis, Groupe VYV, PRO BTP in Talks for Acquisition of Equity Stake in Cegedim Santé

Is Now The Time To Put Cegedim (EPA:CGM) On Your Watchlist?

Investor sentiment improved over the past week

Cegedim SA Provides Revenue Guidance for the Year 2022

Cegedim SA to Report First Half, 2022 Results on Sep 20, 2022

Cegedim Provides Revenue Guidance for the Year 2021

First half 2021 earnings released: EPS €0.47 (vs €0.34 loss in 1H 2020)

Consensus forecasts updated

Is Cegedim SA (EPA:CGM) Trading At A 26% Discount?

Should You Think About Buying Cegedim SA (EPA:CGM) Now?

Consensus forecasts updated

Cegedim Provides Revenue Guidance for the Year 2021

Cegedim (EPA:CGM) Seems To Use Debt Quite Sensibly

Cegedim's (EPA:CGM) Shareholders Are Down 33% On Their Shares

Full year 2020 earnings released: EPS €0.78 (vs €0.20 in FY 2019)

Cegedim SA Provides Earnings Guidance for the Year 2021

Are Investors Undervaluing Cegedim SA (EPA:CGM) By 43%?

New 90-day low: €23.20

What Is Cegedim SA's (EPA:CGM) Share Price Doing?

Analysts update estimates

What Is The Ownership Structure Like For Cegedim SA (EPA:CGM)?

Cegedim SA (EPA:CGM) Delivered A Weaker ROE Than Its Industry

What Does Cegedim's (EPA:CGM) CEO Pay Reveal?

Does Cegedim's (EPA:CGM) Statutory Profit Adequately Reflect Its Underlying Profit?

Market bids up stock over the past week

New 90-day high: €27.50

Cegedim's (EPA:CGM) Stock Price Has Reduced 26% In The Past Three Years

New 90-day low: €22.30

Analysts lower EPS estimates to €0.88

Analysts lower EPS estimates to €1.21

New 90-day low: €23.50

New 90-day low - €26.40